Emerging RNA Therapy Platforms: The Next Generation Genetic Medicines

11:00 AM - 12:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 208
The advent of mRNA vaccines, accelerated by the global SARS-Cov-2 pandemic, marked the beginning of a Golden Age of RNA. Globally, there are 15+ RNA therapies that are approved and over 500 programs in preclinical/clinical development (according to ASGCT and Informa Pharma Intelligence). The large majority of these programs are RNAi, Antisense, and mRNA modalities. Here, we will look ahead, discuss the current landscape of emerging modalities with key innovators, and discuss their implications as next generation genetic medicines.
Founding/Managing Partner
Bioluminescence Ventures
Origination Partner
Flagship Pioneering
Founder & CEO
Atomic AI
Chief Medical Officer
Replicate Bioscience
SVP, Business Development
ReCode Therapeutics